SeaStar Medical Holding Corporation: Business Overview, Financials & Competitive Analysis

SeaStar Medical Holding Corporation Overview

SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The company's first commercial product, QUELIMMUNE (SCD-PED), was approved by the FDA in 2024 as the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients.

Strategic Profile

SeaStar's platform is based on the Selective Cytopheretic Device (SCD), which neutralizes over-active immune cells and stops cytokine storm-induced hyperinflammation, with development spanning acute kidney injury, cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. The SCD therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling accelerated pathways to approval.

Competitive Landscape

SeaStar operates in the immunomodulation/critical care device market with limited direct competitors in the cytopheretic device space. Broader competitive pressures come from alternative sepsis/AKI management approaches, other critical care devices, and pharmaceutical interventions. The ultra-rare indication for QUELIMMUNE provides significant market protection, though adoption depends on clinical outcomes and reimbursement dynamics.

Industry Context

SeaStar Medical Holding Corporation operates in Medical Devices / Critical Care / Immunomodulation.

Key facts

Founded: 2007 · Headquarters: Denver, Colorado · Market cap: $10.46M